LivaNova Plc, a healthcare company based in the United Kingdom, has a medium risk rating score of 27.5. The company was created through the merger of Cyberonics in the US and Sorin in Italy. LivaNova focuses on cardiovascular and cardiopulmonary solutions, including surgical heart valves, heart-lung machines, and neuromodulation devices for treatment-resistant epilepsy and depression. After the merger, LivaNova sold its cardiac rhythm management and heart valve businesses. The company generates about half of its revenue from the US market, 21% from Europe, and the rest from the rest of the world. This company has a strong ESG score in environment, sustainability, and governance.